Literature DB >> 12476957

Viramidine (Ribapharm).

Dale Barnard1.   

Abstract

Viramidine, an analog of ribavirin is a broad-spectrum antiviral under development by Ribapharm (previously the R&D division of ICN Pharmaceuticals) for the potential treatment of viral infections [378507]. In September 2000, phase I trials began in Europe. In December 2001, the company filed a US IND for the clinical development of viramidine as part of a combination therapy with interferon-afor the treatment of chronic hepatitis C virus (HCV) infection [435007], [441613]; a phase I trial was initiated in the US in late March 2002 [435598]. In November 2002, Ribapharm reported that it would start phase II trials of viramidine in the treatment of chronic HCV by the end of 2002 [469062].

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476957

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  3 in total

1.  Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.

Authors:  Jim Zhen Wu; Gary Larson; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Antiviral nucleoside analogs.

Authors:  Vladimir E Kataev; Bulat F Garifullin
Journal:  Chem Heterocycl Compd (N Y)       Date:  2021-05-14       Impact factor: 1.277

Review 3.  Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design.

Authors:  Jim Zhen Wu; Chin-chung Lin; Zhi Hong
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.